Карточка | Таблица | RUSMARC | |
PHARMACEUTICAL SCIENCES: breakthroughs in research and practice. — HERSHEY: MEDICAL INFOR Science IGI, 2017. — 1 online resource — <URL:http://elib.fa.ru/ebsco/1447283.pdf>.Дата создания записи: 06.01.2017 Тематика: Drug development.; Pharmaceutical industry.; BUSINESS & ECONOMICS / Industries / General Коллекции: EBSCO Разрешенные действия: –
Действие 'Прочитать' будет доступно, если вы выполните вход в систему или будете работать с сайтом на компьютере в другой сети
Действие 'Загрузить' будет доступно, если вы выполните вход в систему или будете работать с сайтом на компьютере в другой сети
Группа: Анонимные пользователи Сеть: Интернет |
Права на использование объекта хранения
Место доступа | Группа пользователей | Действие | ||||
---|---|---|---|---|---|---|
Локальная сеть Финуниверситета | Все | |||||
Интернет | Читатели | |||||
Интернет | Анонимные пользователи |
Оглавление
- Title Page
- Copyright Page
- List of Contributors
- Table of Contents
- Preface
- Section 1: Clinical Trials, Education, and Information Access
- Chapter 1: Overview of Clinical Trial and Pharmacovigilance Process and Areas of Application of Computer System
- Chapter 2: Pharmacogenomics Genome Wise Association Clinical Studies
- Chapter 3: Normalizing Cross-Border Healthcare in Europe via New E-Prescription Paradigms
- Chapter 4: Web 2.0 Tools in Biomedical and Pharmaceutical Education
- Chapter 5: Open Access Initiatives in Medical Biology
- Section 2: Drug Delivery and Patient Care
- Chapter 6: Application of Nanoparticles as a Drug Delivery System
- Chapter 7: Non-Ionic Surfactant Vesicles (Niosomes) as New Drug Delivery Systems
- Chapter 8: Cancer Drug Delivery
- Chapter 9: CNS Targeted Nanoparticle Drug Delivery
- Chapter 10: Engineered Gellan Polysaccharides in the Design of Controlled Drug Delivery Systems
- Chapter 11: Improving Pharmaceutical Care through the Use of Intelligent Pharmacoinformatics
- Chapter 12: Personalized Medicine in the Era of Genomics
- Chapter 13: Role of Resveratrol (RES) in Regenerative Medicine
- Chapter 14: Strategies for Expanding Access and Improving the Quality of Pharmaceutical Services
- Chapter 15: An Overview of Therapeutic Applications
- Chapter 16: Bioinformatics and Its Therapeutic Applications
- Chapter 17: A Perspective on the Phytopharmaceuticals Responsible for the Therapeutic Applications
- Chapter 18: Resealed Erythrocytes as Drug Carriers and Its Therapeutic Applications
- Chapter 19: Sedation and Analgesia
- Section 3: Functional Foods
- Chapter 20: Phytonutrients of Nutraceutical Importance
- Chapter 21: Prediction of Structural and Functional Aspects of Protein
- Chapter 22: Flavonoids
- Chapter 23: Food Allergy and Food Poisoning
- Chapter 24: Food and Cardiac Health
- Section 4: Molecular Modeling and Drug Design
- Chapter 25: Molecular-Docking-Based Drug Design and Discovery
- Chapter 26: Role of Molecular Docking in Computer-Aided Drug Design and Development
- Chapter 27: Molecular-Docking-Based Anti-Allergic Drug Design
- Chapter 28: Molecular Docking Technique to Understand Enzyme-Ligand Interactions
- Chapter 29: Molecular Modelling, Dynamics, and Docking of Membrane Proteins
- Chapter 30: Molecular Docking Challenges and Limitations
- Chapter 31: Different Types of Molecular Docking Based on Variations of Interacting Molecules
- Chapter 32: The Comparison of Docking Search Algorithms and Scoring Functions
- Chapter 33: Application of Docking Methodologies in QSAR-Based Studies
- Chapter 34: Protein Structure Prediction Using Homology Modeling
- Chapter 35: QSAR Studies on Bacterial Efflux Pump Inhibitors
- Chapter 36: QSPR/QSAR Analyses by Means of the CORAL Software
- Chapter 37: 2D and 3D QSAR Studies on a Series of Antichagasic Fenarimol Derivatives
- Chapter 38: The “ETA” Indices in QSAR/QSPR/QSTR Research
- Chapter 39: Importance of Applicability Domain of QSAR Models
- Chapter 40: Molecular Dynamics Simulations for Biological Systems
- Chapter 41: Protein Ligand Interaction Fingerprints
- Chapter 42: Protein-Protein Docking
- Chapter 43: Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase
- Chapter 44: Rational Drug Design Rational Drug Design
- Chapter 45: Smart, Innovative and Intelligent Technologies Used in Drug Designing
- Section 5: Nanostructures and Technology
- Chapter 46: Hybrid Plasmonic Nanostructures
- Chapter 47: Implementation of Nanoparticles in Cancer Therapy
- Chapter 48: Nanomedicine
- Chapter 49: Nanosuspensions in Nanobiomedicine
- Chapter 50: Quantitative Nanostructure-Activity Relationship Models for the Risk Assessment of NanoMaterials
- Chapter 51: QSAR-Based Studies of Nanomaterials in the Environment
- Chapter 52: Stratagems of Nanotechnology Augmenting the Bioavailability and Therapeutic Efficacy of Traditional Medicine to Formulate Smart Herbal Drugs Combating
- Section 6: Toxicology
- Chapter 53: Toxic Effects of Engineered Nanoparticles on Living Cells
- Chapter 54: Cyanobacterial Toxins in Water Sources and Their Impacts on Human Health
- Chapter 55: Pharmaceuticals and Personal Care Products as Emerging Water Contaminants
- Chapter 56: Toxicological Effects of Carbon Nanotubes
- Chapter 57: Understanding Toxicity of Nanomaterials in Biological Systems
- Chapter 58: Quantitative Structure-Activity/Property/Toxicity Relationships through Conceptual Density Functional Theory-Based Reactivity Descriptors
- Chapter 59: Quasi-SMILES for Nano-QSAR Prediction of Toxic Effect of Al2O3 Nanoparticles
- Index
Статистика использования
Количество обращений: 0
За последние 30 дней: 0 Подробная статистика |